1. Home
  2. MDWD vs DXLG Comparison

MDWD vs DXLG Comparison

Compare MDWD & DXLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • DXLG
  • Stock Information
  • Founded
  • MDWD 2000
  • DXLG 1976
  • Country
  • MDWD Israel
  • DXLG United States
  • Employees
  • MDWD N/A
  • DXLG N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • DXLG Clothing/Shoe/Accessory Stores
  • Sector
  • MDWD Health Care
  • DXLG Consumer Discretionary
  • Exchange
  • MDWD Nasdaq
  • DXLG Nasdaq
  • Market Cap
  • MDWD 172.6M
  • DXLG 156.7M
  • IPO Year
  • MDWD 2014
  • DXLG 1987
  • Fundamental
  • Price
  • MDWD $16.48
  • DXLG $2.32
  • Analyst Decision
  • MDWD Strong Buy
  • DXLG Buy
  • Analyst Count
  • MDWD 1
  • DXLG 2
  • Target Price
  • MDWD $28.00
  • DXLG $3.50
  • AVG Volume (30 Days)
  • MDWD 46.6K
  • DXLG 260.2K
  • Earning Date
  • MDWD 11-26-2024
  • DXLG 11-22-2024
  • Dividend Yield
  • MDWD N/A
  • DXLG N/A
  • EPS Growth
  • MDWD N/A
  • DXLG N/A
  • EPS
  • MDWD N/A
  • DXLG 0.15
  • Revenue
  • MDWD $20,141,000.00
  • DXLG $484,954,000.00
  • Revenue This Year
  • MDWD $30.16
  • DXLG N/A
  • Revenue Next Year
  • MDWD $18.44
  • DXLG $6.38
  • P/E Ratio
  • MDWD N/A
  • DXLG $15.48
  • Revenue Growth
  • MDWD N/A
  • DXLG N/A
  • 52 Week Low
  • MDWD $8.41
  • DXLG $2.19
  • 52 Week High
  • MDWD $24.00
  • DXLG $4.76
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 44.78
  • DXLG 30.60
  • Support Level
  • MDWD $15.53
  • DXLG $2.43
  • Resistance Level
  • MDWD $16.85
  • DXLG $3.06
  • Average True Range (ATR)
  • MDWD 0.69
  • DXLG 0.16
  • MACD
  • MDWD -0.07
  • DXLG -0.06
  • Stochastic Oscillator
  • MDWD 32.87
  • DXLG 2.60

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets.

Share on Social Networks: